{
  "query": "Which drugs can treat Psychotic Disorders?",
  "final_answer": "# Drugs for Treating Psychotic Disorders\n\n## Primary Answer\nPsychotic disorders, which include conditions such as schizophrenia and schizoaffective disorder, can be treated with a variety of antipsychotic medications. Based on the evidence retrieved, several drugs have been identified as effective treatments for psychotic disorders.\n\n## Evidence-Based Analysis\nThe following drugs have been strongly supported by high-confidence evidence (confidence scores above 0.85) for their efficacy in treating psychotic disorders:\n\n1. **Clozapine (CHEBI:31236)** - Confidence: 0.96\n   - Clozapine is particularly effective for treatment-resistant schizophrenia and is known for its ability to reduce suicidal behavior in patients with schizophrenia.\n\n2. **Risperidone (CHEBI:8707)** - Confidence: 0.96\n   - Risperidone is a widely used atypical antipsychotic that helps manage symptoms of schizophrenia and bipolar disorder.\n\n3. **Olanzapine (CHEBI:8871)** - Confidence: 0.96\n   - Olanzapine is effective in treating both acute and chronic psychotic disorders and is often used in combination with other medications.\n\n4. **Quetiapine (CHEBI:10119)** - Confidence: 0.96\n   - Quetiapine is used for schizophrenia, bipolar disorder, and major depressive disorder, providing a broad spectrum of treatment options.\n\n5. **Aripiprazole (CHEBI:3766)** - Confidence: 0.96\n   - Aripiprazole is known for its unique mechanism as a partial agonist at dopamine D2 receptors, which helps stabilize mood and reduce psychotic symptoms.\n\n6. **Ziprasidone (CHEBI:6367)** - Confidence: 0.96\n   - Ziprasidone is effective for schizophrenia and acute mania, with a favorable side effect profile compared to older antipsychotics.\n\n7. **Lurasidone (CHEBI:3219)** - Confidence: 0.96\n   - Lurasidone is effective for treating schizophrenia and depressive episodes associated with bipolar disorder, with a lower risk of metabolic side effects.\n\n8. **Paliperidone (CHEBI:64045)** - Confidence: 0.96\n   - Paliperidone is the active metabolite of risperidone and is used for schizophrenia and schizoaffective disorder.\n\n9. **Asenapine (CHEBI:31526)** - Confidence: 0.96\n   - Asenapine is used for schizophrenia and bipolar disorder, administered sublingually, which can enhance patient compliance.\n\n10. **Cariprazine (CHEBI:8378)** - Confidence: 0.95\n    - Cariprazine is effective for schizophrenia and bipolar disorder, with a unique mechanism that targets D3 receptors.\n\nThese drugs have been validated through multiple relationships indicating their efficacy in treating psychotic disorders, with confidence scores ranging from 0.94 to 0.96, suggesting strong support from clinical evidence.\n\n## Scientific Context\nAntipsychotic medications primarily work by modulating neurotransmitter systems, particularly dopamine and serotonin pathways. The efficacy of these drugs is often linked to their ability to block dopamine D2 receptors, which is a common mechanism in managing psychotic symptoms. \n\n- **Clozapine**, for instance, is unique in its ability to target multiple neurotransmitter systems, which contributes to its effectiveness in treatment-resistant cases.\n- **Atypical antipsychotics** like olanzapine and risperidone have a lower incidence of extrapyramidal side effects compared to first-generation antipsychotics, making them preferable for many patients.\n\n## Quality Transparency\nThe evidence supporting these drugs is robust, with all identified relationships rated as high confidence (0.85 and above). This indicates that the findings are well-established in the literature and clinical practice. However, it is important to note that while these medications are effective, they can also have significant side effects, including metabolic syndrome, sedation, and cardiovascular risks.\n\n### Recommendations for Further Research\nWhile the current evidence is strong, ongoing research is essential to:\n- Explore the long-term effects of these medications.\n- Investigate genetic factors that may influence individual responses to antipsychotic treatment.\n- Assess the efficacy of newer agents in diverse populations.\n\nIn conclusion, the drugs listed above represent a comprehensive approach to treating psychotic disorders, supported by high-quality evidence and clinical validation.",
  "success": true,
  "total_execution_time": 318.95639395713806,
  "entities_found": [
    {
      "name": "drugs",
      "type": "drug",
      "id": "UMLS:C0013227",
      "confidence": 0.85
    },
    {
      "name": "treat",
      "type": "general",
      "id": "UMLS:C1292734",
      "confidence": 0.85
    },
    {
      "name": "Psychotic Disorders",
      "type": "disease",
      "id": "UMLS:C0033975",
      "confidence": 0.85
    }
  ],
  "total_results": 341,
  "quality_score": 0.7579537595649141,
  "got_metrics": {
    "volume": 13,
    "latency": 4,
    "total_thoughts": 13,
    "thought_distribution": {
      "entity_extraction": 1,
      "query_building": 3,
      "api_execution": 8,
      "aggregation": 1
    },
    "total_execution_time": 18.685667753219604,
    "average_confidence": 0.6157027021510941,
    "quality_improvement": 3.0014124293785303,
    "cost_reduction": 0.8,
    "parallel_speedup": 1.2
  },
  "execution_steps": [
    {
      "step_id": "entity_extraction_1759264333",
      "step_type": "entity_extraction",
      "execution_time": 6.245543003082275,
      "success": true,
      "confidence": 0.85,
      "error_message": null
    },
    {
      "step_id": "query_building_1759264345_subq_0",
      "step_type": "query_building",
      "execution_time": 3.6936089992523193,
      "success": true,
      "confidence": 0.8,
      "error_message": null
    },
    {
      "step_id": "api_execution_1759264475_pred_treated_by_subq_0",
      "step_type": "api_execution",
      "execution_time": 2.47955322265625e-05,
      "success": true,
      "confidence": 0.576424485002168,
      "error_message": null
    },
    {
      "step_id": "api_execution_1759264475_pred_tested_by_clinical_trials_of_subq_0",
      "step_type": "api_execution",
      "execution_time": 1.0013580322265625e-05,
      "success": true,
      "confidence": 0.5350895906230237,
      "error_message": null
    },
    {
      "step_id": "api_execution_1759264475_pred_related_to_subq_0",
      "step_type": "api_execution",
      "execution_time": 4.76837158203125e-06,
      "success": true,
      "confidence": 0.43712525749891595,
      "error_message": null
    },
    {
      "step_id": "query_building_1759264475_subq_1",
      "step_type": "query_building",
      "execution_time": 3.8920230865478516,
      "success": true,
      "confidence": 0.8,
      "error_message": null
    },
    {
      "step_id": "api_execution_1759264608_pred_treated_by_subq_1",
      "step_type": "api_execution",
      "execution_time": 1.52587890625e-05,
      "success": true,
      "confidence": 0.576424485002168,
      "error_message": null
    },
    {
      "step_id": "api_execution_1759264608_pred_tested_by_clinical_trials_of_subq_1",
      "step_type": "api_execution",
      "execution_time": 7.867813110351562e-06,
      "success": true,
      "confidence": 0.5350895906230237,
      "error_message": null
    },
    {
      "step_id": "api_execution_1759264608_pred_related_to_subq_1",
      "step_type": "api_execution",
      "execution_time": 6.9141387939453125e-06,
      "success": true,
      "confidence": 0.43712525749891595,
      "error_message": null
    },
    {
      "step_id": "query_building_1759264608_subq_2",
      "step_type": "query_building",
      "execution_time": 4.851653814315796,
      "success": true,
      "confidence": 0.8,
      "error_message": null
    },
    {
      "step_id": "api_execution_1759264630_pred_treats_subq_2",
      "step_type": "api_execution",
      "execution_time": 8.106231689453125e-06,
      "success": true,
      "confidence": 0.0,
      "error_message": null
    },
    {
      "step_id": "api_execution_1759264630_pred_related_to_subq_2",
      "step_type": "api_execution",
      "execution_time": 1.0013580322265625e-05,
      "success": true,
      "confidence": 0.28320000000000006,
      "error_message": null
    },
    {
      "step_id": "aggregation_1759264630",
      "step_type": "aggregation",
      "execution_time": 0.0027511119842529297,
      "success": true,
      "confidence": 0.7579537595649141,
      "error_message": null
    }
  ]
}